Related Experiment Video
Updated: Aug 10, 2026

Measuring Granulocyte and Monocyte Phagocytosis and Oxidative Burst Activity in Human Blood
Published on: September 12, 2016
Effects of CNI-1493 on human granulocyte functions
Hana Abdalla1, Tony Forslund, Thomas Schön
1Department of Molecular and Clinical Medicine, Division of Medical Microbiology, Faculty of Health Sciences, Linköping University, S-581 85 Linköping, Sweden. hanab@imk.liu.se
Abstract:
During acute bacterial infections such as sepsis and meningitis, activation of inflammatory mediators such as nitric oxide (NO) plays a crucial role in both pathogenesis and host defense. We have previously reported that CNI-1493, a macrophage deactivator, reduced mortality in infant rats infected with Haemophilus influenzae type b (Hib) with associated decrease in the number of granulocytes in the infected tissue. The aim of the present study was to investigate how CNI-1493 affects granulocytes and macrophages in vitro. Murine macrophages (RAW 264.7) pre-incubated with CNI-1493 prior to activation with lipopolysaccharide (LPS)/interferon gamma (IFNgamma) had decreased NO production measured as NO(2)(-)/NO(3)(-) levels and reduction in inducible NO-synthase (iNOS) expression. Reactive oxygen species (ROS) production was increased in formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated granulocytes following CNI-1493 treatment, whereas F-actin content, motility and chemotaxis were decreased under the same conditions. The effects of CNI-1493 on both NO production in LPS/IFNgamma-activated macrophages and ROS production, F-actin content, motility and chemotaxis in granulocytes, may contribute to the reduced inflammatory response and increased survival in Hib-infected animals treated with CNI-1493.
Insights
CNI-1493, a macrophage deactivator, reduces nitric oxide (NO) production in macrophages and alters granulocyte function. These effects may explain its survival benefits in bacterial infections like Haemophilus influenzae type b (Hib).
Area of Science:
- Immunology
- Pharmacology
Background:
- Nitric oxide (NO) and inflammatory mediators are key in bacterial infections like sepsis and meningitis.
- CNI-1493, a macrophage deactivator, previously reduced mortality in infant rats infected with Haemophilus influenzae type b (Hib).
Purpose of the Study:
- To investigate the in vitro effects of CNI-1493 on granulocytes and macrophages.
Main Methods:
- Murine macrophages (RAW 264.7) were pre-incubated with CNI-1493 before activation with lipopolysaccharide (LPS)/interferon gamma (IFNgamma).
- Granulocyte function was assessed after CNI-1493 treatment and stimulation with formylmethionyl-leucyl-phenylalanine (FMLP).
- Nitrite/nitrate levels and inducible NO-synthase (iNOS) expression were measured in macrophages.
- Reactive oxygen species (ROS) production, F-actin content, motility, and chemotaxis were measured in granulocytes.
Main Results:
- CNI-1493 decreased NO production and iNOS expression in activated macrophages.
- CNI-1493 increased ROS production in FMLP-stimulated granulocytes.
- CNI-1493 decreased F-actin content, motility, and chemotaxis in granulocytes.
Conclusions:
- CNI-1493's effects on macrophage NO production and granulocyte function may contribute to reduced inflammation and improved survival in Hib-infected animals.
- These findings elucidate the mechanisms underlying CNI-1493's therapeutic potential in bacterial infections.

